Plain-English translation of NCT04722523 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a type of immunotherapy drug, works well when combined with standard chemotherapy and another immunotherapy drug called in people with advanced head and neck squamous cell carcinoma. The goal is to see if this combination treatment given before surgery can shrink tumors effectively enough that patients may not need radiation therapy after their surgery.
Currently, patients with advanced head and neck cancer typically need surgery followed by radiation therapy (sometimes with chemotherapy) to prevent cancer from returning. This trial is exploring whether giving this new combination treatment before surgery instead could be more effective and potentially spare patients from needing radiation therapy afterward.
You likely qualify if…
You likely don't qualify if…
You would receive the combination treatment (chemotherapy plus the two immunotherapy drugs) over several weeks before undergoing surgery to remove your tumor. Your doctors will monitor you closely during treatment with blood tests and imaging scans to track how well the treatment is working. After surgery, your care team will assess whether you need radiation therapy or if the pre-surgery treatment was effective enough to avoid it.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States